Portfolio Holdings Detail for ISIN IE00BN92ZL31
Stock Name / FundiShares MSCI World Paris-Aligned Climate UCITS ETF USD (Dist)
Issuer
Entity holding fund iShares III Public Limited Company
Entity Type
Entity LEI 549300PZLRJB7M8H1057
ETF TickerWPAD(USD) Euronext Amsterdam

Holdings detail for MRK

Stock NameMarks Electrical Group PLC
TickerMRK(GBX) LSE
TYPECommon Stock
CountryUK
ISINGB00BM8Q5G47
LEI2138007KN8TKPIXIQE92
TickerMRK(EUR) F

Show aggregate MRK holdings

News associated with MRK

Surprising Analyst 12-Month Target For FDL
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-22 08:04:45
IWD, JNJ, MCD, MRK: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $565.9 million dollar inflow -- that's a 0.9% increase week over w - 2025-09-18 13:26:06
Daiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation
(RTTNews) - Daiichi Sankyo Company Limited (DSKYF) and Merck & Co Inc. (MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for their raludotatug deruxtecan for the treatment of adults with platinum-resistant epithelia - 2025-09-15 08:43:59
Peter Lynch Detailed Fundamental Analysis - MRK
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-12 10:32:51
Guru Fundamental Report for MRK - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-11 10:33:21
Notable ETF Inflow Detected - VYM, JNJ, MRK, CME
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $440.7 million dollar inflow -- that's a 0.7% increase week over - 2025-09-10 11:50:46
MRK Factor-Based Stock Analysis - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-10 10:34:14
Daiichi Sankyo And Merck : Ifinatamab Deruxtecan Shows Promising Results In Phase 2 ES-SCLC Trial
(RTTNews) - Daiichi Sankyo (DSKYF, 4568.T) and Merck & Co Inc. (MRK) announced that Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small c - 2025-09-08 02:18:22
Peter Lynch Detailed Fundamental Analysis - MRK
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-05 10:33:56
Pre-Market Most Active for Sep 5, 2025 : OPEN, TSLL, SCAG, SQQQ, MRK, NVDA, KO, AVGO, SNAP, FIG, WMT, NIO
The NASDAQ 100 Pre-Market Indicator is up 147.96 to 23,780.97. The total Pre-Market volume is currently 100,628,631 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is +0.27 at $6.23, with 12,819,663 shares trade - 2025-09-05 09:29:53
Guru Fundamental Report for MRK - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-04 10:32:25
MRK Factor-Based Stock Analysis - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-09-03 10:34:47
Peter Lynch Detailed Fundamental Analysis - MRK
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-29 10:33:23
MRK's Strong Dividend History Helps it Reach 'Top Dividend Stock of the Dow'
Merck & Co Inc (Symbol: MRK) has been named as the ''Top Dividend Stock of the Dow'', according to Dividend Channel, which published its most recent ''DividendRank'' report. The report noted that among the components of the Dow Jones Industrial Average, MRK shares displayed b - 2025-08-28 08:50:04
MRK Factor-Based Stock Analysis - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-27 10:34:49
MRK Quantitative Stock Analysis - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-26 10:34:02
iShares MSCI ACWI ETF Experiences Big Outflow
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ETF (Symbol: ACWI) where we have detected an approximate $429.5 million dollar outflow -- that's a 1.9% decrease week over week (f - 2025-08-25 13:36:45
Peter Lynch Detailed Fundamental Analysis - MRK
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-22 10:34:21
Dow Movers: WMT, MRK
In early trading on Thursday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.2%. Year to date, Merck has lost about 13.8% of its value. And the worst performing Dow component thus far on the day is Walmart, tr - 2025-08-21 11:27:42
MRK Factor-Based Stock Analysis - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-20 10:34:00
After Hours Most Active for Aug 19, 2025 : CSX, INTC, MRK, NVDA, IBN, KO, FUN, PEP, CX, WMT, HTZ, QQQ
The NASDAQ 100 After Hours Indicator is down -1.71 to 23,383.06. The total After hours volume is currently 259,932,235 shares traded.The following are the most active stocks for the after hours session: CSX Corporation (CSX) is -0.04 at $36.48, with 11,794,785 shares traded. Ove - 2025-08-19 17:24:59
Daiichi Sankyo Announces Breakthrough Therapy Designation For Ifinatamab Deruxtecan
(RTTNews) - Daiichi Sankyo announced that Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. The FDA g - 2025-08-18 08:36:51
The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey
Analysts spotlight Merck, Palo Alto Networks, Freeport-McMoRan, and Espey as innovation, contract wins, and industry trends shape growth prospects. - 2025-08-15 12:44:00
Noteworthy ETF Outflows: SUSL, MCD, DIS, MRK
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares ESG MSCI USA Leaders ETF (Symbol: SUSL) where we have detected an approximate $84.6 million dollar outflow -- that's a 8.7% decrease week ov - 2025-08-15 11:49:25
Peter Lynch Detailed Fundamental Analysis - MRK
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati - 2025-08-15 10:31:59
Top Analyst Reports for Merck, Palo Alto & Freeport
Merck leans on Keytruda growth and pipeline expansion, Palo Alto rides subscription security demand, and Freeport benefits from electrification-driven copper demand. - 2025-08-14 17:46:00
Stocks See Support As Bessent Calls for a Big Rate Cut
The S&P 500 Index ($SPX ) (SPY ) on Wednesday rose +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) rose +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +0.04%. September E-mini S&P futures (ESU25 ) rose +0.32%, and September E-mini Nasdaq futures (NQU25 ) fell... - 2025-08-14 15:15:33
MRK April 2026 Options Begin Trading
Investors in Merck & Co Inc (Symbol: MRK) saw new options become available today, for the April 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 246 days until expiration the newly available contra - 2025-08-14 14:30:24
Stocks See Support As Bessent Calls for a Big Rate Cut
The S&P 500 Index ($SPX ) (SPY ) on Wednesday rose +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) rose +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +0.04%. September E-mini S&P futures (ESU25 ) rose +0.32%, and September E-mini Nasdaq futures (NQU25 ) fell... - 2025-08-14 14:05:26
Stocks See Support As Bessent Calls for a Big Rate Cut
The S&P 500 Index ($SPX ) (SPY ) on Wednesday rose +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) rose +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +0.04%. September E-mini S&P futures (ESU25 ) rose +0.32%, and September E-mini Nasdaq futures (NQU25 ) fell... - 2025-08-14 12:17:47

iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Dist) MRK holdings

DateNumber of MRK Shares HeldBase Market Value of MRK SharesLocal Market Value of MRK SharesChange in MRK Shares HeldChange in MRK Base ValueCurrent Price per MRK Share HeldPrevious Price per MRK Share Held
2025-09-18 (Thursday)21,733USD 1,771,891MRK holding increased by 8475USD 1,771,8910USD 8,475 USD 81.53 USD 81.14
2025-09-17 (Wednesday)21,733USD 1,763,416MRK holding increased by 1087USD 1,763,4160USD 1,087 USD 81.14 USD 81.09
2025-09-16 (Tuesday)21,733USD 1,762,329MRK holding increased by 1521USD 1,762,3290USD 1,521 USD 81.09 USD 81.02
2025-09-15 (Monday)21,733USD 1,760,808USD 1,760,808
2025-09-12 (Friday)21,733USD 1,799,710USD 1,799,710
2025-09-11 (Thursday)21,733USD 1,850,565USD 1,850,565
2025-09-10 (Wednesday)21,733USD 1,826,224USD 1,826,224
2025-09-09 (Tuesday)21,733USD 1,838,829USD 1,838,829
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MRK by for IE00BN92ZL31

Show aggregate share trades of MRK

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-07-25BUY31085.22083.840 83.978GBX 26,033 82.21
2025-07-07SELL-30981.54080.150 80.289GBX -24,809 82.15 Profit of 575 on sale
2025-06-16SELL-1,53181.35079.710 79.874GBX -122,287 82.61 Profit of 4,188 on sale
2025-06-10SELL-88581.88079.330 79.585GBX -70,433 82.69 Profit of 2,748 on sale
2025-06-02SELL-604 76.250* 83.17 Profit of 50,237 on sale
2025-05-22BUY29578.36076.680 76.848GBX 22,670 83.99
2025-05-13SELL-309 76.630* 85.00 Profit of 26,266 on sale
2025-05-12BUY309 80.430* 85.11
2025-04-25SELL-1,23683.28078.060 78.582GBX -97,127 86.26 Profit of 9,491 on sale
2025-04-11BUY61879.44076.360 76.668GBX 47,381 89.51
2025-03-20BUY899 94.730* 94.53
2025-03-17BUY295 94.790* 94.54
2025-03-10BUY927 95.230* 94.65
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MRK

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-191,053,2942,0243,869,11627.2%
2025-09-181,184,9228,0053,015,34039.3%
2025-09-171,616,76818,7303,647,85344.3%
2025-09-161,223,7119603,598,70934.0%
2025-09-151,814,7678,4204,295,96242.2%
2025-09-122,018,4637,5573,506,69457.6%
2025-09-111,493,7285,3993,180,82847.0%
2025-09-102,013,1025,3353,313,84760.7%
2025-09-091,075,1375,5052,373,81745.3%
2025-09-082,147,2042,4483,731,34357.5%
2025-09-051,440,1149,9482,983,29648.3%
2025-09-041,439,7261,1215,661,88725.4%
2025-09-031,849,1033,5534,699,60739.3%
2025-09-022,193,136115,1354,314,82650.8%
2025-08-291,545,05711,4203,841,71540.2%
2025-08-281,559,7666,1695,284,88829.5%
2025-08-271,383,4767,8383,737,50637.0%
2025-08-261,328,2351,2292,869,94446.3%
2025-08-252,177,2005,5783,771,31357.7%
2025-08-221,523,3527,4973,248,57546.9%
2025-08-212,449,66018,5405,416,96945.2%
2025-08-201,189,29116,6923,133,34538.0%
2025-08-191,722,6512,3313,737,68946.1%
2025-08-181,150,9372,8222,604,34444.2%
2025-08-151,795,3941,6733,415,80852.6%
2025-08-142,198,5622,2724,496,39848.9%
2025-08-131,885,48019,5373,953,04547.7%
2025-08-121,593,84410,3603,185,66750.0%
2025-08-11990,4053,6052,886,69034.3%
2025-08-081,224,37811,1872,672,27945.8%
2025-08-071,718,6615,3564,504,85038.2%
2025-08-062,028,9271,8824,007,25250.6%
2025-08-051,573,6816,0493,579,53444.0%
2025-08-041,568,9759443,301,80147.5%
2025-08-011,718,70113,8534,079,64242.1%
2025-07-313,367,7552,6646,082,64455.4%
2025-07-302,253,4585,8784,162,63654.1%
2025-07-295,939,07236,24911,111,79553.4%
2025-07-282,243,2356,7394,563,91349.2%
2025-07-251,302,4376,9002,889,20745.1%
2025-07-241,156,3972,5702,732,35142.3%
2025-07-231,879,40020,2804,001,02547.0%
2025-07-221,628,7541,7733,592,84745.3%
2025-07-211,900,56312,5715,188,43236.6%
2025-07-181,536,7621,2463,463,05944.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.